首页> 外文期刊>International journal of urology: official journal of the Japanese Urological Association >Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients.
【24h】

Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients.

机译:通过逆转录-聚合酶链反应检测膀胱癌患者中循环MUC7阳性细胞。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: To determine whether MUC7 gene expression can be used as a bladder cancer marker in peripheral blood. METHODS: Nested reverse transcription-polymerase chain reaction (RT-PCR) was performed on four types of bladder cancer cell lines (RT4, T24, EJ-1 and TCC) and the peripheral blood of 38 (31 superficial disease and seven invasive disease) bladder cancer patients and 18 subjects with urinary tract infections or other non-malignant conditions to determine the expression of MUC7. RESULTS: No MUC7 gene expression was detected in control subjects. MUC7-positive cells were detected in all bladder cancer cell lines and in 18 of 38 (47.4%) peripheral blood samples of bladder cancer patients. Based on the tumor stage, MUC7 was detected in 11 of 29 (37.9%) patients with superficial disease (Ta and T1) and in seven of nine (77.7%) invasive disease patients (>/=T2). There was a significant difference between superficial and invasive disease (P = 0.042). Based on tumor grade, we could not detect MUC7 in five patients with grade 1, in five of 15 patients (33.3%) with grade 2 and in 13 of 18 patients (72.2%) with grade 3. There was a significant difference between grades 1 and 3 (P = 0.007) and grades 2 and 3 (P = 0.025). CONCLUSIONS: These results suggest that MUC7 is a highly specific marker for bladder cancer and may be a useful method for the molecular staging and management of bladder cancer.
机译:背景:为了确定MUC7基因表达是否可以用作外周血中的膀胱癌标志物。方法:对四种类型的膀胱癌细胞系(RT4,T24,EJ-1和TCC)和38名外周血(31种浅表疾病和7种浸润性疾病)进行巢式逆转录聚合酶链反应(RT-PCR)膀胱癌患者和18位患有尿路感染或其他非恶性疾病的受试者,以确定MUC7的表达。结果:在对照受试者中未检测到MUC7基因表达。在所有膀胱癌细胞系和38例膀胱癌患者外周血样本中的18例(47.4%)中检测到MUC7阳性细胞。根据肿瘤的分期,在29名(37.9%)浅表疾病(Ta和T1)患者中有11名和9名(77.7%)浸润性疾病患者(> / = T2)中检测到MUC7。浅表性疾病和浸润性疾病之间存在显着差异(P = 0.042)。根据肿瘤等级,我们无法检测到5例1级患者,15例2级患者中的5例(33.3%)和18例3级患者中的13例(72.2%)。等级之间存在显着差异1和3(P = 0.007)以及2和3年级(P = 0.025)。结论:这些结果表明MUC7是膀胱癌的高度特异性标志物,可能是用于膀胱癌的分子分期和管理的有用方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号